Evidence supporting the use of: Phytocannabinoid (unspecified)
For the health condition: Muscle Tone (lack of)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Phytocannabinoids, particularly cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), have been studied for their effects on muscle tone, especially in the context of spasticity associated with neurological disorders such as multiple sclerosis (MS). Clinical trials and systematic reviews provide moderate evidence that certain cannabinoid formulations can reduce muscle spasticity. For example, nabiximols (a standardized oromucosal spray containing THC and CBD) is approved in several countries for the treatment of moderate to severe spasticity in MS patients who have not responded adequately to other therapies. The mechanism is thought to involve modulation of cannabinoid receptors (CB1 and CB2) in the central nervous system, which play a role in regulating muscle tone and neural excitability.

However, the evidence base is strongest for MS-related spasticity, with less robust data for other causes of low muscle tone (hypotonia). Most clinical studies focus on spasticity (increased muscle tone), not hypotonia (decreased muscle tone), and there is limited research on the use of phytocannabinoids specifically for the latter. Reported side effects, variable efficacy, and legal/regulatory issues also limit widespread use. In summary, while there is moderate scientific support for the use of phytocannabinoids in improving abnormal muscle tone in specific neurological contexts, the evidence for their use in treating lack of muscle tone per se is limited.

More about Phytocannabinoid (unspecified)
More about Muscle Tone (lack of)

Products containing Phytocannabinoid (unspecified)

We currently have no products on Vitabase that contain this ingredient.